Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company whose news flow centers on the development of gamma-delta (γδ) T cell therapies and engagers for cancer and autoimmune diseases. Company press releases and SEC-referenced communications highlight regular updates on clinical trial progress, preclinical data presentations, and corporate developments.
Investors following IN8bio news can expect detailed coverage of its key programs, including INB-100 for leukemias in the post-transplant setting and DeltEx™ Drug-Resistant Immunotherapy (DRI) γδ T cells in INB-200 and INB-400 trials for newly diagnosed glioblastoma. Recent announcements describe extended median progression-free survival in GBM patients receiving repeated doses of DeltEx DRI γδ T cells, favorable safety profiles without dose-limiting toxicities, and multi-center data presented at major scientific meetings such as the American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology (SNO).
News items also cover IN8bio’s γδ T cell engager pipeline, including INB-619, a CD19-targeted, pan-γδ T cell engager. The company has reported preclinical data from lupus and systemic lupus erythematosus (SLE) donor models, showing complete B cell depletion with minimal inflammatory cytokine release, and has presented these findings at conferences such as the American College of Rheumatology (ACR) Convergence Meeting and the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
In addition, IN8bio issues news releases on its proprietary manufacturing platform, scientific awards, financial results and financing transactions. Readers of INAB news can use this page to monitor clinical milestones, data readouts, scientific conference presentations and material corporate events that the company discloses through press releases and related filings.
IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will present at the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 12:00pm ET. The conference will showcase IN8bio’s innovative gamma-delta T cell therapies for solid and liquid tumors, emphasizing their unique ability to differentiate healthy from diseased tissues. Currently, IN8bio is conducting two Phase 1 clinical trials for its leading candidates: INB-200 targeting glioblastoma and INB-100 for leukemia patients. A Phase 2 trial, INB-400, is also set to begin post-IND clearance. For further details, visit IN8bio.com.
IN8bio, a clinical-stage biopharmaceutical company, reported promising initial data from its Phase 1 trial of INB-200 in newly diagnosed glioblastoma multiforme (GBM). All three patients in Cohort 2 exceeded the median progression-free survival of seven months, with responses ongoing beyond 1.5 years. The company aims to start a Phase 2 trial of INB-400 by Q3 2023 and anticipates submitting an IND for INB-410 in 2H 2023. No serious adverse events related to treatment have been reported, indicating a favorable safety profile.
IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical leader in gamma-delta T cell therapies, announced that CEO William Ho will present at the Biotech Showcase 2023 on January 9, 2023. The company will participate in a panel discussion on innovative gene and cell therapy approaches on January 10. This event will occur at the Hilton San Francisco Union Square, coinciding with the 41st Annual J.P. Morgan Healthcare Conference from January 9-11, 2023. IN8bio is currently advancing several clinical trials for its lead products targeting glioblastoma and leukemia.
IN8bio announced positive results from the Phase 1 trial of INB-100, a gamma-delta T cell therapy for hematological malignancies. Patients in the first cohort showed durable responses, remaining progression-free for over 2.5 years. Notably, 4 patients treated at the first dose level have maintained remission, with no dose-limiting toxicities reported. Enrollment for Cohort 2 has begun, with updates anticipated in Q2 2023. The results highlight INB-100's potential to improve cure rates in high-risk acute myeloid leukemia patients undergoing haploidentical stem cell transplantation.
IN8bio has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of INB-400, targeting newly diagnosed glioblastoma. The trial aims to assess the safety and efficacy of genetically modified DeltEx drug-resistant immunotherapy cells at various U.S. medical centers. This milestone marks IN8bio's first company-sponsored IND and sets the stage for further exploration of its DeltEx platform across solid tumor cancers. A conference call will be held on December 12 to discuss updated data from the ongoing Phase 1 trial of INB-100.
IN8bio, Inc. (Nasdaq: INAB) reported significant progress in its third quarter 2022 updates. The Phase 1 trial of INB-100 in leukemia patients showed durable morphologic complete responses with no dose-limiting toxicities. The company raised $9.8 million through an equity offering, boosting its cash position to $27.6 million. Additionally, IN8bio partnered with the Dunbar CAR T-Cell Program for INB-400 GMP production and expanded its R&D efforts, although it reported a net loss of $7.4 million for the quarter.
IN8bio, Inc. (Nasdaq: INAB) announced promising early results from its ongoing Phase 1 trial of INB-100, targeting high-risk acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplant. Notably, all three patients in Cohort 1 are alive and progression-free, with response durations exceeding 12 to 26.5 months. The safety profile remains manageable, with no dose-limiting toxicities observed. Updated data will be presented at the upcoming ASH Annual Meeting on December 11, 2022, highlighting the potential of INB-100 to impact AML treatment paradigms.
IN8bio, a clinical-stage biopharmaceutical company, has announced that CEO William Ho will present at two investor conferences in November 2022. He will participate in the BioFuture 2022 on November 8, presenting at 9:30 a.m. ET and again at 2:30 p.m. ET. Additionally, he will present at the Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. ET. The Stifel presentation will be available live and as a replay on the company's website. IN8bio is focused on developing gamma-delta T cell therapies for solid and liquid tumors.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will speak at the “Cell Therapy in Solid Tumors” panel during the Cantor Oncology & HemOnc Conference on September 28, 2022, at 1:45 p.m. ET. IN8bio is focused on developing innovative gamma-delta T cell therapies for solid and liquid tumors through its DeltEx platform. The company is conducting Phase 1 clinical trials for INB-200, targeting newly diagnosed glioblastoma, and INB-100 for leukemia patients undergoing stem cell transplantation, alongside its preclinical programs.
IN8bio, Inc. (Nasdaq: INAB) has partnered with the UofL Health - Brown Cancer Center for exclusive access to a GMP manufacturing facility, essential for its INB-400 Phase 2 clinical program targeting glioblastoma. This collaboration aims to enhance efficiency in T-cell therapy production, addressing a significant bottleneck for cell therapy companies. The partnership potentially allows for future expansion into commercial-scale manufacturing, supporting broader access to innovative immunotherapies for cancer patients.